Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Spermosens

0,01 SEK

0,00 %

Mindre end 1K følgere

SPERM

Spotlight Stock Market

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
0,00 %
+6,67 %
-11,11 %
-8,57 %
-52,24 %
-50,77 %
-97,03 %
-
-99,34 %

Spermosens are active in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes products for male infertility and individually tailored fertility treatments. Research and development is conducted via its own technological platform that analyzes sperm quality, which is further used for medical data and potential fertilization. The largest operations are in the Nordic market.

Læs mere
Markedsværdi
20,31 mio. SEK
Aktieomsætning
10,69 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning t

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
11.2
2026

Årsrapport '25

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelsefor 3 timer siden

Spermosens announces outcome of exercise of warrants series TO 4

Spermosens
Selskabsmeddelelse24.11.2025, 16.12

Spermosens announces last day of trading for warrants of series TO 4

Spermosens
Selskabsmeddelelse18.11.2025, 09.21

Spermosens receives patent approval in China

Spermosens

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse12.11.2025, 08.04

Spermosens AB (publ) INTERIM REPORT JANUARY - SEPTEMBER 2025

Spermosens
Selskabsmeddelelse4.11.2025, 16.21

Spermosens receives patent approval in Israel

Spermosens
Selskabsmeddelelse3.11.2025, 11.31

Spermosens receives patent approval in Mexico

Spermosens
Selskabsmeddelelse22.10.2025, 09.17

Spermosens receives patent approval in Canada

Spermosens
Selskabsmeddelelse20.8.2025, 07.38

Spermosens AB (publ) INTERIM REPORT JANUARY - JUNE 2025

Spermosens
Pressemeddelelse7.8.2025, 06.30

Spermosens provides status update following successful clinical study

Spermosens
Selskabsmeddelelse17.6.2025, 12.16

Spermosens announces outcome of exercise of warrants series TO 5

Spermosens
Selskabsmeddelelse16.6.2025, 09.15

Spermosens AB Announces Results from Annual General Meeting on 16 June 2025

Spermosens
Selskabsmeddelelse13.6.2025, 11.04

Chairman and CEO of Spermosens exercise TO5 warrants

Spermosens
Selskabsmeddelelse11.6.2025, 10.48

Spermosens concludes clinical study with statistically significant results supporting the diagnostic value of JUNO-Checked

Spermosens
Selskabsmeddelelse5.6.2025, 19.09

Spermosens: The capital raise and issue announced in March 2025 is approved by Inspectorate of Strategic Products

Spermosens
Selskabsmeddelelse5.6.2025, 10.27

Last day of trading in warrants series TO 5 in Spermosens is 12 June 2025

Spermosens
Selskabsmeddelelse2.6.2025, 06.45

Spermosens: The subscription price for warrants of series TO 5 has been determined - the exercise period begins today

Spermosens
Selskabsmeddelelse26.5.2025, 10.06

Spermosens publishes annual report for the financial year 2024

Spermosens
Selskabsmeddelelse15.5.2025, 06.51

Spermosens: NOTICE OF ANNUAL GENERAL MEETING 2025 IN SPERMOSENS AB (publ)

Spermosens
Selskabsmeddelelse7.5.2025, 07.10

Spermosens AB (publ)INTERIM REPORT JANUARY - MARCH 2025

Spermosens
Pressemeddelelse30.4.2025, 10.48

Spermosens provides update on clinical progress, partner discussions and financing

Spermosens
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.